Atara Biotherapeutics (NASDAQ:ATRA) Posts Earnings Results

Key Points

• Atara Biotherapeutics reported earnings of $0.19 per share, exceeding analysts' expectations by $0.51, as analysts had predicted a loss of ($0.32).
• Despite a positive earnings report, the company's stock fell by $0.63 to $10.32 during midday trading.
• Insider Innovation Ltd Panacea increased its stake in Atara Biotherapeutics by acquiring 19,335 shares, totaling nearly $186,389, reflecting a confidence in the company's future prospects.

Atara Biotherapeutics (NASDAQ:ATRA - Get Free Report) posted its earnings results on Monday. The biotechnology company reported $0.19 earnings per share for the quarter, topping analysts' consensus estimates of ($0.32) by $0.51, Zacks reports.

Atara Biotherapeutics Stock Performance

Shares of Atara Biotherapeutics stock traded down $0.63 during midday trading on Monday, hitting $10.32. The company had a trading volume of 41,748 shares, compared to its average volume of 65,116. The company has a 50 day moving average of $9.56 and a 200 day moving average of $8.02. Atara Biotherapeutics has a 52-week low of $5.01 and a 52-week high of $18.70.

Insider Buying and Selling at Atara Biotherapeutics

In related news, major shareholder Innovation Ltd Panacea purchased 19,335 shares of the business's stock in a transaction that occurred on Thursday, July 17th. The shares were bought at an average price of $9.64 per share, for a total transaction of $186,389.40. Following the purchase, the insider directly owned 1,350,000 shares of the company's stock, valued at approximately $13,014,000. This represents a 1.45% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 4.00% of the stock is owned by insiders.

Institutional Trading of Atara Biotherapeutics

A hedge fund recently raised its stake in Atara Biotherapeutics stock. Geode Capital Management LLC increased its stake in Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Free Report) by 2.5% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 60,136 shares of the biotechnology company's stock after buying an additional 1,457 shares during the period. Geode Capital Management LLC owned 1.01% of Atara Biotherapeutics worth $464,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 70.90% of the company's stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.